View clinical trials related to Femoropopliteal Artery Disease.
Filter by:- Prospective, randomized, controlled, multi-center study - A total of 240 subjects with femoropopliteal artery disease will be included according to inclusion and exclusion criteria. - Patients will be randomized in a 1:1 manner into IVUS-guided or angiography-guided intervention group. - Second 1:1 randomization into dual antiplatelet therapy (aspirin + clopidogrel) or triple antiplatelet therapy (aspirin + clopidogrel + cilostazol) is optional - All patients will be treated with drug-coated balloons (In.PACT Admiral) for femoropopliteal lesions. - Bare metal self-expandable stents will be used in addition according to findings of IVUS or angiography such as severity of arterial dissection or residual stenosis. - Patients will be followed clinically for 1 year after the procedure. - Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.
The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.